Description
Release form
Film-coated tablets.
Packing
28 pcs.
Pharmacological action
Zanidip-Recordati – a blocker of “slow” calcium channels. Lercanidipine is a racemic mixture of right- (R) and left-handed (S) stereoisomers, a derivative of 1,4-dihydropyridine, is able to selectively block the flow of calcium ions into the cells of the vascular wall, heart cells and smooth muscle cells. The mechanism of the hypotensive effect is due to the direct relaxing effect on vascular smooth muscle cells. It has a prolonged antihypertensive effect. The therapeutic effect is achieved 5-7 hours after ingestion and its duration persists for a day (24 hours). Due to its high selectivity to vascular smooth muscle cells, there is no negative inotropic effect. Lercanidipine is a metabolically neutral drug and does not significantly affect the content of lipoproteins and apolipoproteins in the blood serum, and also does not change the lipid profile in patients with arterial hypertension.
Indications
Essential mild to moderate hypertension.
Contraindications
Hypersensitivity,
decompensated heart failure, unstable angina pectoris, aortic stenosis, recent myocardial infarction (within 1 month),
severe hepatic impairment, renal impairment (CK less than 12 ml / min, s, children) not using reliable contraception, pregnancy, lactation,
childhood and adolescence (up to 18 years).
For LF containing lactose (optional): lactose intolerance, galactosemia, glucose / galactose malabsorption syndrome.
Caution. Renal and / or liver failure, CVD (without pacemaker), coronary heart disease, LV dysfunction, advanced age.
Special instructions
During treatment, care must be taken when driving vehicles and engaging in potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
Composition
1 tab. contains:
Active substances: lercanidipine hydrochloride 20 mg.
Excipients: lactose monohydrate – 60 mg, MCC – 78 mg carboxymethyl starch sodium 31 mg povidone K30 – 9 mg magnesium stearate – 2 mg.
Shell (dosage 20 mg): Opadry pink (02F25077) – 6 mg (hypromellose, talc, titanium dioxide (E171), macrogol 6000, dye iron oxide red (E172).
Dosage and administration of
Zanidip-Recordati taken orally, in the morning, at least 15 minutes before meals, without chewing, drinking plenty of water, 10 mg once a day.
Dose may be increased to 20 mg (depending on individual effect). Increasing the dose to 20 mg is carried out 2 weeks after the start of the drug.
In case of mild or moderate renal or hepatic insufficiency, increase the dose to 20 mg per day with caution.
Side effects
WHO statistics: very often 1/10 appointments, often 1/100 appointments, not often 1/1000 appointments, rarely 1/10000 appointments, very rarely less than 1/10000 appointments.
On the part of the nervous system: rarely – drowsiness infrequently – headache, dizziness
On the part of the immune system: very rarely – increased sensitivity
From the cardiovascular system: not often – tachycardia, sensation of palpitations “flushing” of blood to the skin of the face rarely – angina pectoris is very rare – fainting, pronounced decrease in blood pressure, chest pain,
myocardial infarction From the digestive system: rarely – nausea, vomiting, diarrhea, abdominal pain, dyspepsia, very rarely – increased activity of “liver” enzymes (reversible)
From the skin: rarely – skin rash
From the musculoskeletal system: rarely – myalgia
From the urinary system: rarely – polyuria
General disorders and local reactions: not often – peripheral edema, rarely – asthenia, increased fatigue very rarely – gingival hyperplasia.
Overdose
Symptoms: peripheral vasodilation with a marked decrease in blood pressure and reflex tachycardia, an increase in the frequency and duration of angina attacks, myocardial infarction.
Treatment: symptomatic therapy.
Storage conditions
At a temperature not exceeding 30 ° C. Keep out of reach of children.
Form of Treatment
tablets
Recordati Chemical and Pharmaceutical Industry, Italy
